A Greek SME with significant research and professional experience in the field of biomedical engineering and mainly in the emerging molecular imaging technology has developed three innovative systems for small-sized animal imaging.
As regards their current activities, the Greek company provides advanced imaging services in the field of preclinical research for the study of new drugs, biomolecules, nanoparticles and animal diseases to both private and academic clients. These services include characterization of biomolecules and nanoparticles, functionalization, radiolabelling, ex vivo biodistribution and in vivo imaging with SPECT (Single Photon Emission Computed Tomography), CT (Computed Tomography) and PET (Positron Emission Tomography). On a contract basis they can undertake part of a study or perform an entire protocol, including both in vitro, ex vivo and in vivo study.
Recently the company extended also their imaging services towards imaging of samples such as implants, bones, teeth and other materials. In addition, they are also exploring radioisotopic imaging for monitoring the fate of nanoparticles in plants, as tools for efficient delivery of fertilizers in agriculture and other biotechnology domains.
Concerning the offered technology, the company has developed three high-end systems for mouse and rat imaging: a) a Micro Computed Tomography (microCT) with 50 micrometers (um) resolution, which provides high detail anatomical information and b) a Micro Single Photon Emission Computed Tomography (microSPECT) with 600 um resolution, for detailed functional studies, and c) a custom SPECT/PET/CT system, which is continuously optimized for improving performance and allows the imaging of higher energy isotopes and long lived isotopes.
In addition, the company owns an individually ventilated cages (IVC) system for animal hosting to support a full study in-house. Through strategic collaborations, they are able to enrich their imaging portfolio by including optical imaging and Magnetic Resonance Imaging (MRI), while developing new software tools for processing of multimodal data.
The proposed systems have already been successfully applied in various applications including nanomedicine, oncology, regenerative medicine, orthopaedics, cardiology and other model diseases providing comprehensive imaging support.
The Greek company is looking for interested partners from both academic and private sectors of which molecular imaging is a crucial part of their activities. For this reason, the Greek company offers the three different systems as alternatives in order to provide specialised imaging services at low cost, depending on each customer needs and capabilities under the framework of services agreement. Also, they are searching for academic and research groups in order to participate collaboratively in H2020 projects undertaking the performance of complete imaging studies for the in vivo evaluation of radiopharmaceuticals, nanoparticles and other biomolecules. The considered type of agreement is research cooperation agreement.